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Osteoporosis is defined as a progressive systemic skeletal disease 
characterised by low bone mass and micro-architectural deterioration 
of bone tissue with a consequent increase in bone fragility and 
susceptibility to fracture.
There is still uncertainty about the diagnosis and management 
of osteoporosis and osteopenia (low bone mass) and the medical 
management of low trauma (fragility) fractures, particularly in 
the very elderly. Recommendations from authorities including 
the National Osteoporosis Foundation of South Africa (NOFSA), 
National Osteoporosis Foundation of the USA (NOF) and National 
Osteoporosis Guideline Group of the UK (NOGG) are often not 
implemented.1-3 Responsibility for management moreover is divided 
between many different specialties.
Diagnosis
Osteoporosis and osteopenia (low bone mass) are now widely 
diagnosed by measuring bone mineral density (BMD) using dual 
energy X-ray absorptiometry (DEXA) of the upper femur and lumbar 
spine. The criteria for the diagnosis of osteoporosis and osteopenia, 
however, vary between the different authorities with regard to the site 
at which BMD is measured and the number of bone sites included.
The World Health Organization (WHO) designates ‘osteoporosis’ 
as a BMD 2.5 standard deviations (SD) or more below the young 
adult mean value for women (a T-score equal to or less than -2.5 SD 
in postmenopausal women). A BMD measurement of between -1 SD 
and -2.5 SD is designated as ‘osteopenia’ or ‘low bone mass’.4 The WHO 
recommends that osteoporosis and osteopenia be diagnosed solely on 
the BMD measurement of the femoral neck, using the data of the 
National Health and Nutrition Examination Survey (NHANES) for 
Caucasian women aged 20 - 29 years as the normal reference range. 
The BMD of the femoral neck alone is recommended for diagnosing 
osteoporosis and osteopenia because of its higher predictive value 
for future fractures. Prediction of fracture risk is claimed not to be 
improved by using multiple sites for the measurement of BMD. The 
spine is not regarded as suitable, particularly in the elderly, because 
of the high prevalence of osteo-arthritis and spinal abnormalities that 
may affect BMD measurements.
The International Society for Clinical Densitometry (ISCD) 
recommends that osteoporosis be diagnosed in postmenopausal 
women and men aged 50 and older if the lowest level of the T-score 
of the femoral neck or the total upper femur or the lumbar spine 
is -2.5 or less, and that osteopenia be diagnosed if the lowest level 
of the T-score is -1.0 or less but above -2.5.5 Measurement of the 
lumbar spine is based on the mean of L1 - L4 vertebrae, excluding 
any vertebra that is more than 1 SD from an adjacent vertebra but 
including a minimum of two vertebrae.
NOFSA recommends that osteoporosis and osteopenia be 
diagnosed by the International. Society for Clinical Densitometry 
(ISCD) criteria or the presence of a fragility fracture (with or without 
BMD measurement) in postmenopausal women and men over 50 
years of age:1 
•	 T-score <-2.5 of the femoral neck or total femur or lumbar spine 
inserted)
•	 T-score -1.0 to -2.5 (osteopenia) with two or more clinical risk 
factors including age 75 years or older
•	 A prior osteoporotic fracture of hip, humerus, pelvis, rib or wrist, 
irrespective of BMD. 
The female reference data for women are applied to the T-score in 
men as recommended by the WHO. NOFSA also recommends that 
all patients qualifying for a BMD measurement should have an X-ray 
of the spine or a DEXA-based vertebral fracture assessment, using 
the Genant semi-quantitative system (grade 1 - 3).6 A reduction in 
vertebral height of at least 20% or 4 mm is required to diagnose a 
vertebral fracture. 
BMD measurements can be used for diagnosis of osteoporosis and 
osteopenia in individuals or for population screening to determine 
those at increased fracture risk. NOGG recommends that BMD 
measurements should only be used for case finding, as BMD 
measurements have a high specificity but low sensitivity for future 
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fractures.3 NOFSA recommends BMD testing of all women 65 years 
and older, all men 70 years or older, and all women and men with 
clinical risk factors for osteoporosis and osteopenia, including all 
those who have had a fracture after age 40 or with known causes of 
secondary osteoporosis.1
Assessment of fracture risk
BMD measurements are a continuum, and the risk of fracture 
approximately doubles with each decrease in SD below the young 
adult mean. BMD, however, accounts for less than 50% of bone 
strength, and many factors related to BMD and independent of BMD 
affect both bone strength and fracture risk 
 The WHO combined these factors in a fracture risk assessment, 
the FRAX score (with or without BMD measurement of the femoral 
neck), to give a 10-year probability of the risk of future hip fracture 
or of a major osteoporotic fracture (clinical fracture of the spine, hip, 
forearm or humerus) in women and men 50 years of age or older 
(Table 1).7 A FRAX tool for assessing fracture risk probability is 
freely available online (www.shef.ac.uk/FRAX). The FRAX score is 
primarily recommended for identifying individual women or men for 
specific treatment of osteoporosis. 
The FRAX score depends on the prevalence of fractures and the 
mortality in any group or country. It has been validated in the UK and 
Sweden and evaluated in other countries with differing fracture and 
mortality rates, including the USA. Modified FRAX scores and tables 
of fracture probability have been published for these countries.8,9 In 
the USA FRAX models for Asians, blacks and Hispanics have also 
been developed because their hip and osteoporotic fracture rates are 
lower than those in USA whites. No data are available for the fracture 
rates for different ethnic groups in South Africa.
The FRAX fracture risk assessment tool has limitations, and in 
particular does not include the number and recentness of previous 
fractures, the risk of falls and the dose and duration of glucocorticoids. 
The risk of a further fracture is highest in the first few years after a 
fracture and the risk of a vertebral fracture is increased 5-fold in the 
first year after a vertebral fracture. FRAX may underestimate fracture 
risk in individuals with recent fracture, those with recent falls, and 
those receiving high doses of glucocorticoids. Fracture risk scores 
that include a history of falls have been introduced including the 
Qfracture score in the UK and the Garvan Fracture Risk Calculator 
(GFRC) in the USA.10,11 The GFRC is a web-based tool that includes 
recent falls (1, 2 and >2 falls) and number of previous fractures (1, 
2 and >2), but does not include some risk factors included in FRAX. 
FRAX underestimates fracture risk in patients with 2 or more previous 
fractures or one or more recent falls, but GFRC underestimates fracture 
risk in women with a parental history of hip fracture and in those 
with secondary osteoporosis. The difficulties and objections raised 
regarding the FRAX tool are discussed in ‘Frequently Asked Questions’ 
on its website. NOFSA proposed an integrated approach to screening 
and management based on FRAX but recognising its limitations, and 
has an algorithm for the selection of women and men aged 50 years 
or older for BMD testing based on clinical risk factors (including 
advanced age) and for treatment (Fig. 1).1
The problem of osteopenia
The ‘Geoffrey Rose Prevention Paradox’ applies to many chronic 
diseases, including osteopenia: ‘a large number of people at small 
risk give rise to more cases than the small number who are at high 
risk’. In most countries less than half of women and men who 
sustain a fragility fracture have osteoporosis as diagnosed by DEXA 
measurements of BMD. The majority have osteopenia (low bone 
mass). In the NORA (Nordic Research on Ageing) study in the USA 
using peripheral BMD measurement of 149 562 postmenopausal 
women aged 50 - 104 years (mean 64.5 years), only 6.4% of women 
had a BMD of <-2.5 SD (associated with 18% of all fractures and 
26% of hip fractures), but 45.3 % of women had a BMD of <1.0 SD 
(associated with 70% of all fractures and 77% of hip fractures).12 In 
the Rotterdam study of 4 878 women who had DEXA measurements 
of the femoral neck and were followed up for a mean 6.8 years, 
the rate of self-reported non-vertebral fractures was 44% with 
osteoporosis, 43.3% with osteopenia and 12.6% with normal BMD.13 
In an Australian  community study of 616 women who had DEXA 
measurements of the total femur, 124 women had one or more 
Fig. 1. Algorithm for the management of osteoporosis in postmenopausal 
women and men aged 50 years and older.
Table 1. FRAX clinical risk factors7 for the assessment of 
fracture probability
Age Years
Gender Male or female
Low body mass 19 kg/m2
Previous fracture Yes/no, clinical or X-ray hip, 
spine or wrist
Parental history of hip fracture Yes/no
Current glucocorticoid 
treatment
Yes/no, oral, any dose for >3 
months
Current smoking Yes/no
Alcohol intake Yes/ no, 3 or more units daily
Secondary causes of 
osteoporosis*
Yes/no
*Rheumatoid arthritis, type 1 diabetes, hyperthyroidism, hypogonadism, gastro-intestinal 
disease, chronic liver disease, pulmonary disease, organ transplantation.
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fractures. Of the women with fractures, only 26.9% had osteoporosis, 
56.5% had osteopenia and 16.6% had a normal BMD.14 Most women 
and men who suffer from a fragility fracture do not have osteoporosis 
as defined by the WHO. Therefore, assessment of fracture risk 
and diagnosis and treatment should not be limited to those with 
osteoporosis but should include all patients with osteopenia and all 
patients with clinical risk factors for fracture. 
A recent publication from the Study of Osteoporotic Fractures 
Research Group in the USA has related the estimated time interval 
for 10% of women with different degrees of osteopenia to make the 
transition from osteopenia to osteoporosis. Normal BMD was defined 
as a T-score at the femoral neck and total hip of -1.00 or higher and 
osteopenia as a T-score of -1.01 to -2.49. Mild, moderate and advanced 
osteopenia were defined as T-scores of -1.10 to -1.49, -1.50 to -1.99 and 
-2.0 to -2.49, respectively. The intervals between baseline testing and 
development of osteoporosis in 4 957 women aged 67 years and older 
(adjusted for BMI, current oestrogen use and smoking, current or past 
use of oral glucocorticoids and rheumatoid arthritis) in years with 95% 
confidence limits were: normal BMD 16.8 (11.5 - 24.6), mild osteopenia 
17.3 (13.9 - 21.5), moderate osteopenia 4.7 (4.2 - 5.2), advanced 
osteopenia 1.1 (1.0 - 1.3). It is clear that the degree of osteopenia is 
a major factor in predicting the development of osteoporosis and of 
consequent fracture risk and the degree of osteopenia should be taken 
into account in arriving at all treatment decisions 15 
Treatment decisions
Criteria for diagnosis are not the same as those for treating osteoporosis 
and osteopenia. Treatment must be based on assessing future fracture 
risk and on the medical state of each individual. Authorities agree 
that decisions about treatment must be individualised and based on 
good clinical judgement, taking into account patient preferences, 
co-morbidities, previous drug use and risk factors not captured in 
FRAX, and possible under- or overestimation of fracture risk by 
FRAX. Guidelines for treating osteoporosis/osteopenia include the 
recent excellent NOFSA Guideline for the Diagnosis and Management 
of Osteoporosis.1
Management of osteopenia
Women and men with osteopenia are generally considered to be 
at low risk of fracture. They are often managed with advice about 
calcium and vitamin D supplementation and lifestyle changes, but 
are not given any specific therapy. Most clinical trials of specific 
therapies for osteoporosis and osteopenia have focused on patients 
with osteoporosis and/or the presence of hip or vertebral fracture. 
Few randomised controlled trials have been performed on patients 
with osteopenia, but some have included osteopenic patients allowing 
post hoc analyses. In the Fracture Intervention Trial (FIT) 1 and 
FIT 2 trials of patients with osteopenia of the femoral neck with 
and without vertebral fractures, alendronate decreased the risk of 
radiological fractures (relative risk (RR) 0.48, 95% confidence interval 
(CI) 0.41 - 0.81) and of clinical vertebral fractures (RR 0.41, 95% CI 
0.19 - 0.76).16 In the Spinal Osteoporosis Therapeutic Intervention 
SOTI) and TReatment Of Peripheral OSteoporosis (TROPOS) trials 
in women with osteopenia of the lumbar spine, strontium ranelate 
reduced the risk of vertebral fracture in women with no prevalent 
fractures (RR 0.41, 95% CI 0.17 - 0.99) and in women with prevalent 
fractures (RR 0.62, 95% CI 0.44 - 0.88).17 In women with osteopenia 
at both the lumbar spine and femoral neck, treatment with strontium 
ranelate reduced the risk of fracture (RR 0.48, 95% CI 0.24 - 0.96). 
Specific drug treatment appears to be effective and is justified to 
reduce the risk of further fractures in patients with osteopenia, 
particularly those with prevalent fractures.
Management of osteoporosis and osteopenia in the very 
elderly
Very elderly women and men (aged 80 years and over) are the fastest-
growing segment of the population. About 25 - 30% of the population 
burden of all fragility fractures is in women and men over 80, who are 
at high risk for fracture, particularly non-vertebral fracture, because 
of their high prevalence of osteoporosis and osteopenia and high 
incidence of falls. After a hip fracture approximately 20% of patients 
do not survive more than a year and 50% do not regain their previous 
level of independence. Vertebral fractures are associated with back 
pain, height loss, kyphosis and functional disability. The prevalence 
of vertebral deformities increases from 5 - 10% in women in the 50s 
to 45 - 55% of those in the 80s. Only a proportion of older women 
and men with osteoporosis or osteopenia receive specific treatment. 
Some clinicians may consider that patients over 80 years are too old, 
or that it is too late to significantly alter the course of the disease. 
Based on pooled data of 1 392 women aged 80 or over from the HIP, 
VERT-MN and VERT-NA trials, risendronate resulted in a 44% 
reduction in vertebral fractures but not in non-vertebral fractures.18 
In 1 488 women between 80 and 100 years of age from the SOTI 
and TROPOS trials and followed up for 3 years, strontium ranelate 
reduced the risk of vertebral, non-vertebral and clinical symptomatic 
fractures within the first year by 59% (p=0.002), 41% (p=0.027) 
and 37% (p=0.012), respectively.19 At the end of 3 years vertebral, 
non-vertebral and symptomatic clinical fractures were reduced by 
32% (p=0.013), 31% (p=0.011) and 22% (p=0.040), respectively. 
Strontium ranelate was reported to be well tolerated and as safe as 
in younger patients. Women and men are therefore never too old 
for treatment, and it is never too late to treat those with osteoporosis 
or osteopenia, particularly when they have a fragility fracture. 
Responsibility for diagnosis and 
management
Patients with osteoporosis and osteopenia are treated by general 
practitioners and specialists from various disciplines including 
orthopaedics, rheumatology, gynaecology, geriatrics and 
endocrinology. Knowledge and understanding of the diagnosis and 
treatment of osteoporosis and of fragility fractures is increasing 
and new treatment options are being developed. Few specialties 
require training in osteoporosis and metabolic bone diseases for 
higher professional qualification. A good case can be made for the 
establishment of local groups, including generalists and specialists 
who are especially interested in osteoporosis, to agree on referral 
practices and treatment based on local resources. In large hospitals 
an ‘osteoporosis clinic’ including different disciplines may facilitate 
diagnosis and management. There is little doubt that the care of women 
and men with osteoporosis or osteopenia and those with fragility 
fractures, particularly the very elderly, can be enormously improved.
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